HROW

NASDAQ Healthcare

Harrow, Inc. - Common Stock

Drug Manufacturers - Specialty & Generic

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

๐Ÿ“Š Market Data
Price$40.90
Volume469,050
Market Cap1.52B
Beta0.310
RSI (14-Day)66.3
200-Day MA$41.35
50-Day MA$39.27
52-Week High$54.85
52-Week Low$21.12
Forward P/E15.04
Price / Book29.03
๐ŸŽฏ Investment Strategy Scores

HROW scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 48/100โ–ฒ +1
High dividend yield + low volatility
๐Ÿš€ Moon Shot 12/100โ–ฒ +1
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 41/100โ€” 0
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 76/100โ€” 0
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐ŸŽˆ Over-Hyped (76/100) โ€” this strategy Overbought stocks (potential short candidates).

Lowest fit among scored strategies: ๐Ÿš€ Moon Shot (12/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find HROW in your text

Paste any article, transcript, or post โ€” the tool will extract HROW and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.